Clinical Trials Directory

Trials / Completed

CompletedNCT00345384

Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients

Post-Operative Infusion of Low-Dose Dexmedetomidine for the Control of Post-Operative Pain in Thoracotomy Patients: A Randomized, Double-Blind, Controlled Pilot Study

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
38 (actual)
Sponsor
Baylor Research Institute · Academic / Other
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to evaluate the safety, efficacy, hemodynamic and respiratory stability of a low-dose of dexmedetomidine infusion in post-operative surgical in-patients undergoing thoracic surgery after discharge from PACU or ICU.

Detailed description

Dexmedetomidine has sedative and analgesic properties that may reduce the opioid requirement in post-operative patients, thereby decreasing the chance of post-operative respiratory depression that occurs with opioid administration. In addition, patients may be more alert with less opioid medication. Currently, dexmedetomidine is not approved for use longer than twenty-four hours and must only be administered in the Intensive Care Unit where patients can be continuously monitored. This is a prospective, double-blinded, control group pilot study. One group (the control group) will receive a normal saline infusion and the second group (the treatment group) will receive low-dose Dexmedetomidine for up to 24 hours after they are admitted to an open nursing unit (not an Intensive Care Unit). During the surgery, the anesthesiologist will administer dexmedetomidine during the surgical procedure after an optional loading dose. All patients will receive pain medication using a Patient Controlled Analgesia (PCA) pump as per standard practice. In addition, if the physician deems necessary, an On-Q Pain Pump will deliver local anesthetic surrounding the incision under direction of the surgeon. Before discharge from the PACU or ICU, each subject will receive either low-dose dexmedetomidine or normal saline using a continuous infusion pump for up to 24 hours after the subject is discharged from either the PACU or the ICU to an open nursing unit. While on the open nursing unit patient vital signs, oxygen saturation, Ramsay score and pain score will recorded every two hours until the treatment drug is stopped.

Conditions

Interventions

TypeNameDescription
DRUGDexmedetomidineDexmedetomidine titrated over 24 hours
OTHERPlacebo (Normal Saline)

Timeline

Start date
2008-05-01
Primary completion
2010-01-01
Completion
2010-01-01
First posted
2006-06-28
Last updated
2016-02-08
Results posted
2015-08-20

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT00345384. Inclusion in this directory is not an endorsement.